Aventis Closer to U.S. Approval for AIDS-Related Drug

Breaking Research: Read or Listen to the Latest Reports From ICAAC/IDSA 2008 >>

BROWSE TOPICS IN CLINICAL MANAGEMENT:

U.S. Centers for Disease Control and Prevention • U.S. News

Aventis Closer to U.S. Approval for AIDS-Related Drug

March 26, 2004

Paris-based Aventis, France's largest drug firm, is one step closer in getting U.S. approval for Sculptra, its injectable wrinkle-filling drug for patients with AIDS-related wasting condition. An advisory panel unanimously voted to recommend Food and Drug Administration approval of Sculptra for people with HIV, while cautioning against more widespread use. Aventis estimates annual sales of the drug to be as much as 1 billion euros (US$1.2 billion).

Back to other news for March 26, 2004

Search the Newsroom archive

Excerpted from:
New York Times
03.26.04; Bloomberg News

This article was provided by U.S. Centers for Disease Control and Prevention, and is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.